Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Depreciation & Amortization (CF) of $90000.0 for Q1 2026, up 8.43% year-over-year from $83000.0 in Q1 2025, and up 9.76% quarter-over-quarter from $82000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $90000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 8.43% year-over-year to $90000.0; the TTM figure through Mar 2026 stood at $334000.0 (up 5.36% YoY), while the FY2025 annual figure was $327000.0, up 6.17% from the prior year.
- Depreciation & Amortization (CF) rose to $90000.0 in Q1 2026 per OBIO's latest filing, from $82000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $90000.0 in Q1 2026 and bottomed at $48000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $72588.2 across 5 years, with a median of $74000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 47.92% — and 2025, when it retreated 2.38%.
- Orchestra BioMed Holdings' Depreciation & Amortization (CF) stood at $70000.0 in 2022, then grew by 2.86% to $72000.0 in 2023, then rose by 16.67% to $84000.0 in 2024, then declined by 2.38% to $82000.0 in 2025, then climbed by 9.76% to $90000.0 in 2026.
- Business Quant data shows OBIO's Depreciation & Amortization (CF) at $90000.0 in Q1 2026, $82000.0 in Q4 2025, and $81000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 96,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96,000.00 |
| Mar 31, 2026 | 90,000.00 |
| Dec 31, 2025 | 82,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Mar 31, 2024 | 74,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 71,000.00 |
| Jun 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 71,000.00 |
| Dec 31, 2022 | 70,000.00 |
| Sep 30, 2022 | 54,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 48,000.00 |